E-Mail:
Password:
Home | Stock Market Blogs | Financial Tools | Sign Up Free
 

gear headHow cool is this? Shampoo for men in a quart of oil bottle!

Click the banner to get some now and tell the little lady to throw that other stuff in the trash!
Cytomedix, Inc.  
Cytomedix, Inc.
GTFLast: $0.595 ($-0.005)Volume: 49,480Last Trade: 8/5/2010 4:15:10 PM
Today

Today | Last 7 Days | 1 Month | 3 Month | 6 Month | 1 Year
 Options
Quote |  Alerts | | Free Newsletter
 
 Detailed Quote
NYSE:GTF $0.595 ($-0.005 -0.8334%)
Industry: Bio-Technology Sector:
Open: 0.5825 Previous Close: 0.60
Day's High: 0.605 Day's Low: 0.5825
52-Week High: 5.25 52-Week Low: 0.57
 
Bid: 0.51 / 1,000 Ask: 0.6998 / 1,600
Volume: 49,480 Outstanding: 0
Market Cap: -
Cytomedix, Inc. Profile
Co. is a biotechnology company whose business model is premised upon developing, producing, and licensing autologous cellular therapies (i.e., therapies using the patient's own body products) for the treatment of chronic non-healing wounds using its propriety platelet gel and related product therapies. To create the proprietary platelet gel product, the patient's own platelets and other essential blood components for the healing process are separated through centrifugation and formed into a gel (the "AutoloGel ") that is topically applied to a wound under the direction of a physician.
 Cytomedix, Inc. News & Press Releases

Cytomedix Reports First Quarter Financial Results
ROCKVILLE, Md., May 17, 2010 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF) (the "Company"), a leading developer of biologically active regenerative th... [more]



GTF up 22.22% after director buy
( EMAILWIRE.COM , April 30, 2010 ) Boston, MA - InsiderCow.com: JORDEN DAVID EMERSON, director of CYTOMEDIX INC (AMEX: GTF) bought 39000 shares of GTF from the open market on 2010-04-29 according to an SEC filing reported by insidercow.com at 2010-04-... [more]

Cytomedix Acquires Angel Whole Blood Separation System and activAT Autologous Thrombin Processing Ki
Synergistic Products Expand Customer Base, Bring $5 Million in Annual Sales Conference Call Begins April 13th at 10:... [more]

Cytomedix Announces Going Concern Qualification
ROCKVILLE, Md., April 12, 2010 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF) announced today that its audited financial statements for the fiscal year... [more]

Cytomedix Reports Fourth Quarter and Full Year Financial Results
ROCKVILLE, Md., March 29, 2010 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex:GTF), a leading developer of biologically active regenerative therapies for wo... [more]

Cytomedix Reports Third Quarter Financial Results
ROCKVILLE, Md., Nov. 11, 2009 (GLOBE NEWSWIRE) -- Cytomedix, Inc. (NYSE Amex: GTF), a leading developer of biologically active regenerative therapies for wo... [more]

Cytomedix Appoints Martin P. Rosendale Executive Vice President ...
Primenewswire (press release): Cytomedix, Inc. ( AMEX:GTF ) today announced the appointment of Martin P. Rosendale, an industry veteran ...


Home | Blogs | Savings Calculator | Tools | Contact Us | Disclosure | Site Map | Sign UpCopyright 2014
SmallCapWatch, LLC.
Never invest based soley on information from this website or our e-mail and IM alerts